Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal Manchanda

Дата публикации: 23-06-2026 06:35:46

India's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and consumer healthcare. While US FDA approvals for complex generics remain a challenge, innovation and contract manufacturing offer significant future profit pools. Experts anticipate biosimilars could generate substantial revenue, and despite a slow start, GLP-1 drugs show long-term promise. Sun Pharma is highlighted as a preferred domestic investment.

Классификация: Пресс-релизы

Схожие новости

#	Наименование новости	Тональность	Информативность
1	India's defence export boom could hit ₹65,000 crore by 2030; pvt sector startups the real play: Sunil Subramaniam	0	0
2	Defence valuations 'obnoxious'; private banks look strong: Sandip Sabharwal's full market playbook	0	0
3	Rs 1.5 lakh crore behind 2025! Can Jio, NSE and other mega IPOs put 2026 on course for another record year?	0	0
4	«Фармстандарт» инвестирует 7 млрд рублей в производство гормональных и ветеринарных препаратов	0	0
5	India's beauty, personal care market seen at $39 billion by 2030: Flipkart	0	0
6	MF favourites: 12 smallcap stocks surge up to 240% in CY26; 3 turn multibaggers	0	0
7	From raincoats to briefs to diapers: Textile PLI shows green shoots as imports drop, niche exports triple	0	0
8	AI stocks are in a 'blowoff top' phase but the game isn't over yet: Jonathan Schiessl	0	0
9	Raymond Lifestyle looking to capture UK fashion market via FTA: Chairman Gautam Hari Singhania	0	0
10	From Rs 4,900 crore to Rs 41,300 crore: How Sanjeev Bikhchandani turned 135 startups into a 743% return machine	0	0

• Тональность 0
• Информативность 0
• economictimes.indiatimes.com